A first phase I/II study was conducted in patients with metastatic MTC with the F(ab’)2 fragment of the anti-CEA mAb MN-14 labeled with iodine-131 (Juweid et al., 1999). The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.